(VIANEWS) – Shares of Alnylam Pharmaceuticals (NASDAQ Composite: ALNY) slid by a staggering 15.19% to $162.13 at 10:29 EST on Thursday, after two sequential sessions in a row of losses. NASDAQ Composite is falling 0% to $15,235.84, following the last session’s downward trend. This seems, up until now, a somewhat up trend exchanging session today.

Alnylam Pharmaceuticals’s last close was $191.16, 9.83% under its 52-week high of $212.00.

Volume

Today’s last reported volume for Alnylam Pharmaceuticals is 712396 which is 28.14% above its average volume of 555915.

Alnylam Pharmaceuticals’s Sales

Alnylam Pharmaceuticals’s sales growth is 74.6% for the present quarter and 46.7% for the next. The company’s growth estimates for the present quarter and the next is 28% and 23.9%, respectively.

Alnylam Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 112.1%, now sitting on 687.53M for the twelve trailing months.

Volatility

Alnylam Pharmaceuticals’s last week, last month’s, and last quarter’s current volatility was a negative 1.11%, a positive 0.54%, and a positive 1.75%, respectively.

Alnylam Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.47% (last week), 1.41% (last month), and 1.75% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Alnylam Pharmaceuticals’s stock is considered to be overbought (>=80).

Alnylam Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alnylam Pharmaceuticals’s stock is valued at $162.13 at 10:29 EST, way below its 52-week high of $212.00 and way above its 52-week low of $119.29.

Alnylam Pharmaceuticals’s Moving Average

Alnylam Pharmaceuticals’s worth is way under its 50-day moving average of $194.30 and below its 200-day moving average of $172.82.

News about Alnylam Pharmaceuticals (ALNY) today

  • Alnylam pharmaceuticals inc. Q3 adjusted earnings beat estimates. According to today’s article on Business Insider, " -Excluding items, Alnylam Pharmaceuticals Inc. reported adjusted earnings of -$179.84 million or -$1.51 per share for the period. "

More news about Alnylam Pharmaceuticals (ALNY).

LEAVE A REPLY

Please enter your comment!
Please enter your name here